Treatment of co-infection with bancroftian filariasis and onchocerciasis: a safety and efficacy study of albendazole with ivermectin compared to treatment of single infection with bancroftian filariasis

Table 2 Post-drug administration adverse events experienced by individuals with single infection of W. bancrofti

Clinical / Symptoms	(Score) Peak intensity*	Group C (Albendazole + Ivermectin, n = 12) (no. of individuals with symptom)	Group D (Albendazole, n = 13) (no. individuals with symptom)
Fever	1.0	2	0
Itching	1.0	3	0
Palpitation	1.0	1	0
Headache	1.0	0	1
Dizziness	2.0	0	2
Adenitis	2.0	0	1
Oedema	2.0	0	1
Chills	NA	0	0
Lethargy	NA	0	0
Myalgia	NA	0	0
Anorexia	NA	0	0

Scores 0 = no alteration 1 = mild alteration, individual could conduct normal activities without symptom relief. 2 = moderate alteration, individual could proceed with normal daily activity after taking analgesic to alleviate events 3 = severe alteration, individual need be admitted hospital and treated for symptoms. *Mean of highest reaction score for each individual with this sign/symptom. 0, indicates normal, 1 indicates mild; 2 moderate; 3 severe, while fever: 0, indicates 37.0°C – 37.4°C, 1, indicates 37.5°C–37.7°C, 2 indicates 37.8°C–38.8°C, 3 indicates >38.8°C † Group A initially received a single dose of ivermectin (150 μg/kg) plus albendazole (400 mg). Group B received 6 saccharine tablets as a placebo. Five days later the treatment regime was administered in reverse, with the Group A receiving placebo and Group B receiving treatment.